NCT02475837View on ClinicalTrials.gov

Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 26, 2015

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
AV Fistula
Interventions
DRUG

Vorapaxar sulfate

The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.

DRUG

Placebo

The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.

Trial Locations (1)

94305

Stanford Univeristy, Stanford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ken Mahaffey

OTHER

NCT02475837 - Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access | Biotech Hunter | Biotech Hunter